{"product_id":"ccel-vrio-analysis","title":"Cryo-Cell International, Inc. (CCEL): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Cryo-Cell International, Inc. (CCEL)'s market position starts here: a concise VRIO analysis that cuts straight to the core of its competitive advantage. We've rigorously tested its key assets against the criteria of Value, Rarity, Inimitability, and Organization to determine its true staying power. The distilled summary within \u0026amp;O4\u0026amp; holds the answer - is this a sustainable lead or a fleeting edge? Read on below to uncover the critical insights that define Cryo-Cell International, Inc. (CCEL)'s future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 1. Pioneering Brand \u0026amp; Scale in Private Banking\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Cryo-Cell International, Inc. (CCEL) through the VRIO lens, and the immediate takeaway is that its first-mover status is still a powerful, though slightly pressured, asset.\u003c\/p\u003e\n\u003cp\u003eThe brand’s scale and history directly translate into tangible revenue. For the third quarter of fiscal 2025, consolidated revenues - which include processing and storage fees - hit \u003cstrong\u003e$7.83 million\u003c\/strong\u003e. That’s the value component right there: trust equals recurring fees. Still, the market is tight; that same revenue figure represented a \u003cstrong\u003e3%\u003c\/strong\u003e year-over-year dip compared to Q3 fiscal 2024’s \u003cstrong\u003e$8.07 million\u003c\/strong\u003e, showing execution is defintely getting tougher.\u003c\/p\u003e\n\n\u003cp\u003eHere are the core facts supporting this assessment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFounded in \u003cstrong\u003e1989\u003c\/strong\u003e, making it the world’s first private cord blood bank.\u003c\/li\u003e\n\u003cli\u003eEntrusted by \u003cstrong\u003emore than 500,000 parents\u003c\/strong\u003e across 87 countries.\u003c\/li\u003e\n\u003cli\u003ePublic bank partnership with Duke University has provided cord blood for \u003cstrong\u003emore than 700 transplants\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe rarity is historical; being the first is something you can’t buy a ticket to join. Imitability is tough because brand recognition built over 36 years is sticky. Organizationally, they are set up to capitalize on this scale, evidenced by FDA registration and FACT accreditation, but the slight revenue contraction suggests they are not perfectly organized to fend off every competitive push right now.\u003c\/p\u003e\n\n\u003cp\u003eHere is the quick scoring based on the VRIO framework for this core resource:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eImplication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eGenerates \u003cstrong\u003e$7.83 million\u003c\/strong\u003e in Q3 2025 revenue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eWorld's first private bank; unique historical lead.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eBrand equity built over 35+ years is hard to copy quickly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes (with pressure)\u003c\/td\u003e\n\u003ctd\u003eLeverages scale, but Q3 2025 revenue fell \u003cstrong\u003e3%\u003c\/strong\u003e YoY.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained (Temporary Risk)\u003c\/td\u003e\n\u003ctd\u003eFirst-mover advantage provides a durable, though tested, edge.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the success of newer initiatives like ExtraVault services, which are meant to diversify revenue away from the core processing fees that saw a slight decline.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 2. Exclusive PrepaCyte-CB Processing Technology\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This advanced processing technology is claimed to yield superior stem cell quality, which is the core product differentiator for premium pricing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Cryo-Cell International holds the exclusive rights to this specific technology, making it rare among competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High, as it is proprietary technology; imitation requires developing a functionally equivalent, proprietary alternative.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is organized into three reportable segments: (1) cellular processing and cryogenic cellular storage for family use, (2) the manufacture of PrepaCyte® CB Processing System (“PrepaCyte CB”) units, and (3) cryogenic storage of umbilical cord blood stem cells for public use. The overall business saw a total revenue of approximately \u003cstrong\u003e$7.97 million\u003c\/strong\u003e for the fiscal first quarter ended February 28, 2025, and approximately \u003cstrong\u003e$7.9 million\u003c\/strong\u003e for the fiscal second quarter ended May 31, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as technology can be superseded, but currently strong.\u003c\/p\u003e\n\n\u003cp\u003eThe superior performance metrics associated with the PrepaCyte-CB technology, which supports its value proposition, are detailed below:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eMetric\/Data Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (Stem Cell Quality)\u003c\/td\u003e\n\u003ctd\u003eColony-Forming Unit (CFU) Recovery vs. HES Method\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e51%\u003c\/strong\u003e more\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (Stem Cell Quality)\u003c\/td\u003e\n\u003ctd\u003eColony-Forming Unit (CFU) Recovery vs. AutoXpress (AXP) Method\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e70%\u003c\/strong\u003e more\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (Stem Cell Quality)\u003c\/td\u003e\n\u003ctd\u003eRed Blood Cell (RBC) Contamination Reduction\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e99%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (Exclusivity)\u003c\/td\u003e\n\u003ctd\u003eTechnology Rights Status\u003c\/td\u003e\n\u003ctd\u003eExclusive rights to PrepaCyte-CB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (Performance Context)\u003c\/td\u003e\n\u003ctd\u003eFiscal Q1 2025 Revenue (Ended Feb 28, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.97 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (Performance Context)\u003c\/td\u003e\n\u003ctd\u003eFiscal Q2 2025 Revenue (Ended May 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company's organization is structured to leverage this technology across its core segment, which includes the manufacture of PrepaCyte CB units.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe PrepaCyte-CB processing method has been shown to result in a median time to patient neutrophil recovery of \u003cstrong\u003e16 days\u003c\/strong\u003e, compared to \u003cstrong\u003e20 days\u003c\/strong\u003e for the Hespan group in one evaluation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe company reported that more than \u003cstrong\u003e500,000\u003c\/strong\u003e parents from \u003cstrong\u003e87\u003c\/strong\u003e countries have entrusted Cryo-Cell International with their baby's cord blood and cord tissue stem cells.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCryo-Cell's public bank has provided cord blood for more than \u003cstrong\u003e600\u003c\/strong\u003e transplantations as of Q1 FY2025 and more than \u003cstrong\u003e700\u003c\/strong\u003e transplants as of Q2 FY2025.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 3. Duke University License \u0026amp; Therapeutic Pipeline Access\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a pathway to future high-value cellular therapies (e.g., for autism, cerebral palsy) and potential royalty streams, transforming the business model.\u003c\/p\u003e\n\u003cp\u003eThe license grants rights to intellectual property, proprietary processes, and regulatory\/clinical data developed at Duke University's Marcus Center for Cellular Cures, initiated in February 2021. The anticipated indications include autism, cerebral palsy, and traumatic brain injuries, among others. The Company's public bank partnership with Duke has provided cord blood for more than \u003cstrong\u003e700\u003c\/strong\u003e transplants.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Exclusive rights to specific proprietary processes and clinical data from a major research institution like Duke University is highly rare.\u003c\/p\u003e\n\u003cp\u003eDuke has completed or has in progress a total of \u003cstrong\u003e19\u003c\/strong\u003e FDA approved clinical trials related to the Duke License Agreement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very high; replicating this specific, deep academic partnership is extremely difficult.\u003c\/p\u003e\n\u003cp\u003eThe Company is obligated to fund additional clinical trials as necessary to provide proof of efficacy required by the FDA for Biologics License Applications (BLAs).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This is central to their stated transformation into a vertically integrated cellular therapy company, though profitability from this area remains uncertain.\u003c\/p\u003e\n\u003cp\u003eThe assets related to the Duke University Patent and Technology License Agreement were transferred to the wholly-owned subsidiary, Celle Corp., in \u003cstrong\u003eMarch 2024\u003c\/strong\u003e, with a planned spin-off anticipated in Cryo-Cell's 2nd or 3rd fiscal quarters.\u003c\/p\u003e\n\u003cp\u003eThe Company recorded a net loss of \u003cstrong\u003e$9.5 million\u003c\/strong\u003e in fiscal 2023, which included an impairment during the fourth quarter of the assets related to the Duke License Agreement in the amount of \u003cstrong\u003e$13.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, provided the IP remains enforceable and the pipeline yields successful therapies.\u003c\/p\u003e\n\u003cp\u003eThe following table outlines key financial and clinical data points related to the Duke License Agreement:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eCitation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial License Capitalization Cost\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15,372,382\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 Fiscal 2021\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Original License Fee Obligation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOriginal Agreement\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinal Scheduled License Fee Payment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2,000,000\u003c\/strong\u003e (Removed)\u003c\/td\u003e\n\u003ctd\u003eFebruary 23, 2023 (Due Date)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Rate Range on Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7% - 12.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRoyalty Term\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Milestone Payment Added\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1,000,000\u003c\/strong\u003e (Upon FDA approval for autism ctMSC)\u003c\/td\u003e\n\u003ctd\u003eSecond Amendment (Feb 17, 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuke IMPACT Study Accrual\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e137 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 3, 2023\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuke License Asset Impairment Charge\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 Fiscal Year Ended Nov 30, 2023\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinal Research Agreement Payment Made\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$187,400\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Research Agreement, entered into on March 3, 2023, obligated the Company to \u003cstrong\u003e14 equal monthly payments\u003c\/strong\u003e commencing in April 2023, plus a final payment.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTherapeutic indications covered under the license include:\n\u003cul\u003e\n\u003cli\u003eAutism spectrum disorder (ctMSC)\u003c\/li\u003e\n\u003cli\u003eCerebral palsy\u003c\/li\u003e\n\u003cli\u003eTraumatic brain injuries\u003c\/li\u003e\n\u003cli\u003eAdult stroke\u003c\/li\u003e\n\u003cli\u003eMultiple sclerosis\u003c\/li\u003e\n\u003cli\u003eOsteoarthritis (Emory trial readout expected in \u003cstrong\u003e2023\u003c\/strong\u003e)\u003c\/li\u003e\n\u003cli\u003eCOVID-19\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe Company's public bank has provided cord blood for more than \u003cstrong\u003e600\u003c\/strong\u003e transplants (older data) to over \u003cstrong\u003e700\u003c\/strong\u003e transplants (latest data).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 4. Superior Regulatory \u0026amp; Quality Accreditations\n\u003c\/h2\u003e\n\n\u003cp\u003eThe company's commitment to quality is evidenced by its comprehensive suite of regulatory and accreditation achievements, positioning its services at the high end of the market.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAccreditation\/Compliance\u003c\/th\u003e\n\u003cth\u003eStatus\/Detail\u003c\/th\u003e\n\u003cth\u003eYear\/Date Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Registration\u003c\/td\u003e\n\u003ctd\u003eFacility is FDA registered\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ecGMP\/cGTP Compliance\u003c\/td\u003e\n\u003ctd\u003eFacility is cGMP-\/cGTP-compliant\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAABB Accreditation\u003c\/td\u003e\n\u003ctd\u003eIndustry-recognized accreditation for cord blood facility\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFACT Accreditation\u003c\/td\u003e\n\u003ctd\u003eAccreditation for adhering to stringent quality standards\u003c\/td\u003e\n\u003ctd\u003eGranted in \u003cstrong\u003e2014\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eState Licensure\u003c\/td\u003e\n\u003ctd\u003eLicensed in all states requiring licensure\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Bank Transplants Supported\u003c\/td\u003e\n\u003ctd\u003eCord blood provided for transplants through Duke University partnership\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e700\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAchieving FACT and AABB accreditations, alongside FDA registration and cGMP\/cGTP compliance, signals the highest quality standards, supporting premium pricing structures for processing and storage services.\u003c\/li\u003e\n\u003cli\u003eThe core service revenue from processing and storage fees for fiscal 2024 was \u003cstrong\u003e$31.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCompliance with standards such as 21 CFR 1271 (cGTPs) reduces client risk perception regarding the viability and usability of stored stem cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company holds the distinction of being the \u003cstrong\u003efirst U.S. private cord blood bank\u003c\/strong\u003e to receive FACT accreditation.\u003c\/li\u003e\n\u003cli\u003eThe company believes it was the first private cord blood bank to process in a cGMP- and cGTP-compliant facility exceeding current FDA requirements.\u003c\/li\u003e\n\u003cli\u003eThe facility's cryogenic bunker construction, designed to withstand hurricane-force winds and featuring an on-site industrial-grade diesel generator, represents a rare physical asset quality measure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompetitors can pursue AABB and FACT accreditations, but achieving the \u003cstrong\u003ehistorical firsts\u003c\/strong\u003e associated with FACT accreditation and maintaining compliance across all simultaneously presents a moderate barrier.\u003c\/li\u003e\n\u003cli\u003eThe exclusive rights to PrepaCyte-CB processing technology, which recovers more viable stem cells (CFUs), is a distinct, though potentially imitable, technological advantage linked to quality outcomes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company actively markets these accreditations as a key differentiator against competitors who may charge less for services with lower quality assurance.\u003c\/li\u003e\n\u003cli\u003eThe public banking program, in partnership with Duke University, leverages these quality standards to provide cord blood for over \u003cstrong\u003e700\u003c\/strong\u003e transplants.\u003c\/li\u003e\n\u003cli\u003eThe company serves more than \u003cstrong\u003e500,000\u003c\/strong\u003e parents from \u003cstrong\u003e87\u003c\/strong\u003e countries who have entrusted their stem cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCurrently a strong differentiator based on established compliance and historical accreditation milestones.\u003c\/li\u003e\n\u003cli\u003eAdvantage is considered \u003cstrong\u003eTemporary\u003c\/strong\u003e as competitors can pursue and achieve similar certifications over time.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 5. Established Cord Blood \u0026amp; Tissue Storage Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the recurring revenue base from annual storage fees, which increased slightly in H1 FY2025, offsetting lower new processing volumes.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProcessing and Storage Fee Revenue for the three months ended February 28, 2025 (Q1 FY2025): \u003cstrong\u003e$7.87 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProcessing and Storage Fee Revenue for the three months ended May 31, 2025 (Q2 FY2025): \u003cstrong\u003e$7.87 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRecurring annual storage fee revenue showed a \u003cstrong\u003e3% increase\u003c\/strong\u003e for the first six months of fiscal 2025 versus the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eThis increase offset an \u003cstrong\u003e18% decrease\u003c\/strong\u003e in the number of new domestic cord blood specimens processed in the first six months of fiscal 2025 versus the same period in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 FY2025\u003c\/td\u003e\n\u003ctd\u003eQ1 FY2024\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2025\u003c\/td\u003e\n\u003ctd\u003eQ2 FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcessing \u0026amp; Storage Fee Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.87 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.81 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.87 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.97 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The physical, licensed, and accredited facility in Oldsmar, Florida, is a tangible, necessary asset for the core business.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperations, including processing and storage, are handled from the headquarters facility in \u003cstrong\u003eOldsmar, Florida\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFacility is \u003cstrong\u003eFDA registered\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFacility is \u003cstrong\u003ecGMP-\/cGTP-compliant\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFacility is \u003cstrong\u003elicensed in all states requiring licensure\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAccreditations include \u003cstrong\u003eAABB accreditation\u003c\/strong\u003e and \u003cstrong\u003eFACT accreditation\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e500,000 parents\u003c\/strong\u003e from \u003cstrong\u003e87 countries\u003c\/strong\u003e have entrusted the company with their baby's stem cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; building a comparable, fully licensed, and accredited facility takes significant capital and time.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company was the \u003cstrong\u003efirst private cord blood bank\u003c\/strong\u003e to separate and store stem cells in 1992.\u003c\/li\u003e\n\u003cli\u003eAchieving the combination of \u003cstrong\u003eFDA registration\u003c\/strong\u003e, \u003cstrong\u003ecGMP-\/cGTP-compliance\u003c\/strong\u003e, \u003cstrong\u003eAABB accreditation\u003c\/strong\u003e, and \u003cstrong\u003eFACT accreditation\u003c\/strong\u003e presents a significant regulatory and quality hurdle for replication.\u003c\/li\u003e\n\u003cli\u003eExpansion involved the purchase of a \u003cstrong\u003e56,000 square foot facility\u003c\/strong\u003e in Durham, North Carolina, indicating substantial capital outlay for increased capacity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This infrastructure supports the primary revenue stream and is the base from which they are expanding.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue is generated from the initial processing and testing fees and the \u003cstrong\u003eannual storage fees\u003c\/strong\u003e charged each year for storage.\u003c\/li\u003e\n\u003cli\u003eThe Oldsmar facility supports the core U.S.-based business operations.\u003c\/li\u003e\n\u003cli\u003eThe company is expanding capacity with a new facility in Durham, North Carolina, to offer third-party storage services and cellular therapy laboratory development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, due to the sunk cost and regulatory hurdles of replication.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 6. Public Banking Partnership with Duke University\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cp\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: Contributes to corporate reputation, provides access to public cord blood for research, and supports the overall mission of advancing cell therapies.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: A formal public banking partnership with a major research university is not common for private banks.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate; requires a specific, high-level institutional relationship.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: This segment provided \u003cstrong\u003e$43,000\u003c\/strong\u003e in revenue in Q2 FY2025, showing it is a small but strategic part of operations.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary, as partnerships can shift, but currently valuable for optics and R\u0026amp;D support.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 FY2025\u003c\/th\u003e\n\u003cth\u003eQ2 FY2024\u003c\/th\u003e\n\u003cth\u003eFiscal Year 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Banking Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$367,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Transplants (approx.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;700\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;600\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nLicense Agreement with Duke University executed in \u003cstrong\u003eFebruary 2021\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nPublic bank operates donation sites in prominent hospitals such as \u003cstrong\u003eCedars–Sinai Hospital\u003c\/strong\u003e in Los Angeles.\n\u003c\/li\u003e\n\u003cli\u003e\nCryo-Cell has served more than \u003cstrong\u003e500,000 parents\u003c\/strong\u003e from \u003cstrong\u003e87 countries\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nPublic banking revenue for Q2 FY2024 was \u003cstrong\u003e$41,000\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nPublic banking revenue for Fiscal Year 2023 was \u003cstrong\u003e$481,000\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 7. Diversified Service Portfolio (Storage + ExtraVault + Product)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Spreading revenue across storage fees, new services like ExtraVault, and product sales reduces reliance on new customer acquisition alone.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific mix, including the addition of services like ExtraVault, offers a unique combination in the market.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low to moderate; competitors are also expanding service portfolios, but Cryo-Cell International’s specific offerings are unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is actively pursuing product diversification, though product revenue was only \u003cstrong\u003e$35,000\u003c\/strong\u003e in the first six months of FY2025 (sum of Q1: $21,000 and Q2: $14,000).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as diversification is a common industry trend.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial Data for Diversified Portfolio (6 Months Ended May 31, 2025):\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRevenue Stream\u003c\/th\u003e\n\u003cth\u003e6 Months Ended May 31, 2025 (Calculated Sum)\u003c\/th\u003e\n\u003cth\u003eQ2 Ended May 31, 2025\u003c\/th\u003e\n\u003cth\u003eQ2 Ended May 31, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.87 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcessing and Storage Fee Revenue\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.87 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.97 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Banking Revenue\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eAdditional Operational and Strategic Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company is the world's first private cord blood bank, established in 1992.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e500,000\u003c\/strong\u003e parents from \u003cstrong\u003e87\u003c\/strong\u003e countries have entrusted the Company with stem cells.\u003c\/li\u003e\n\u003cli\u003eThe public bank program, in partnership with Duke University, has provided cord blood for more than \u003cstrong\u003e700\u003c\/strong\u003e transplants.\u003c\/li\u003e\n\u003cli\u003eThe Company launched ExtraVault in March 2022.\u003c\/li\u003e\n\u003cli\u003eNet income for Q2 FY2025 was \u003cstrong\u003e$356,000\u003c\/strong\u003e, compared to \u003cstrong\u003e$656,000\u003c\/strong\u003e for Q2 FY2024.\u003c\/li\u003e\n\u003cli\u003eNet income for Q1 FY2025 was approximately \u003cstrong\u003e$283,000\u003c\/strong\u003e, compared to approximately \u003cstrong\u003e$556,000\u003c\/strong\u003e for Q1 FY2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 8. Strategic Focus on Vertical Integration (Biopharma\/Clinics)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Aims to capture value further down the therapeutic chain, potentially leading to higher margins than just storage fees, aligning with their mission. The Company entered into a license agreement with Duke University in February 2021 to begin its transformation into an autonomous, vertically integrated cellular therapy company. The mission includes the intent 'to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide.'\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: The explicit, public strategy to move into biopharmaceutical manufacturing and operating clinics sets them apart from pure storage players. This is evidenced by the launch of ExtraVault in March 2022 to offer expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; this requires entirely new regulatory expertise, capital investment, and operational capabilities outside their historical expertise. The Company's facility is noted as FDA registered, cGMP-\/cGTP-compliant and licensed in all states requiring licensure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: This is a high-risk, high-reward organizational pivot; success is uncertain, but the intent is clear. The Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., which holds the Patent and Technology License Agreement with Duke University, to maximize shareholder value.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary, as it is an ongoing strategic initiative, not a fully realized asset yet. The success of the initiative to expand core business units to include biopharmaceutical manufacturing and operating clinics remains subject to uncertainty.\u003c\/p\u003e\n\u003cp\u003eThe following table provides recent financial context for the core business against which this strategic pivot is being measured:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 Fiscal 2025 (Ended Aug 31, 2025)\u003c\/th\u003e\n\u003cth\u003eQ3 Fiscal 2024 (Ended Aug 31, 2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.83 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.07 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Change (YoY)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-3%\u003c\/strong\u003e decrease\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$749,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.05 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income Per Share (Diluted)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.09\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.13\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther context on the core business and related entities includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMore than \u003cstrong\u003e500,000\u003c\/strong\u003e parents from \u003cstrong\u003e87\u003c\/strong\u003e countries have entrusted the company with stem cells.\u003c\/li\u003e\n\u003cli\u003eThe public bank has provided cord blood for more than \u003cstrong\u003e700\u003c\/strong\u003e transplants.\u003c\/li\u003e\n\u003cli\u003eFiscal 2024 Consolidated Revenues reached \u003cstrong\u003e$32.0 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$31.3 million\u003c\/strong\u003e in Fiscal 2023.\u003c\/li\u003e\n\u003cli\u003eFiscal 2024 Net Income was \u003cstrong\u003e$402,000\u003c\/strong\u003e, compared to a Net Loss of \u003cstrong\u003e$9.5 million\u003c\/strong\u003e in Fiscal 2023.\u003c\/li\u003e\n\u003cli\u003eThe Fiscal 2023 Net Loss was due in part to an impairment of assets related to the Duke License Agreement of \u003cstrong\u003e$13.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCryo-Cell International, Inc. (CCEL) - VRIO Analysis: 9. International Customer Base Across 87 Countries\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates global reach and brand acceptance, providing a broader potential market for future services and therapies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Serving customers in 87 countries is a significant indicator of established international logistics and trust.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; international operations require navigating complex regulations and logistics, which is hard to replicate quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e While the base is international, the company acknowledges that operating globally requires significant management attention and financial resources.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, due to the established network and experience in cross-border compliance.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\u003cp\u003eThe established international footprint is supported by operational standards necessary for global trust:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA registered\u003c\/li\u003e\n\u003cli\u003ecGMP-\/cGTP-compliant\u003c\/li\u003e\n\u003cli\u003eAABB accredited\u003c\/li\u003e\n\u003cli\u003eFACT accreditation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe scale of the international customer base, which has entrusted the company with nearly 500,000 cord blood and cord tissue specimens worldwide, is reflected in the following financial context:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended Nov 30, 2024\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended Nov 30, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Loss)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$402,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($9.5 million)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcessing and Storage Fee Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe cumulative customer base supporting this international presence is reported as exceeding 500,000 parents from 87 countries.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516132778133,"sku":"ccel-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ccel-vrio-analysis.png?v=1740164486","url":"https:\/\/dcf-model.com\/products\/ccel-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}